In DexCom, Inc., v. Abbott Diabetes Care, Inc., 89 F.4th 1370 (Fed. Cir. 2024), the U.S. Court of Appeals for the Federal Circuit affirmed a district court’s denial of a preliminary injunction, finding that a patentee could...more
On Friday, August 25, 2023, the U.S. Court of Appeals For The District Of Columbia Circuit affirmed dismissal of an antitrust action brought by the Federal Trade Commission regarding Endo Pharmaceuticals’s grant of an...more
9/22/2023
/ Antitrust Litigation ,
Appeals ,
Dismissals ,
Federal Trade Commission (FTC) ,
Food and Drug Administration (FDA) ,
FTC Act ,
FTC v Actavis ,
Licenses ,
Patent Act ,
Pharmaceutical Patents ,
SCOTUS ,
Sherman Act
On Tuesday, August 11, 2020, the Ninth Circuit reversed and vacated Judge Lucy Koh’s controversial, post-bench trial decision in FTC v. Qualcomm Inc., 411 F. Supp. 3d 658 (N.D. Cal. 2019), regarding whether Qualcomm violated...more
8/17/2020
/ Anticompetitive Behavior ,
Antitrust Violations ,
Appeals ,
Cell Phones ,
Federal Trade Commission (FTC) ,
FRAND ,
FTC Act ,
Injunctive Relief ,
Intellectual Property Protection ,
IP License ,
Monopolization ,
OEM ,
Patent Royalties ,
Popular ,
Qualcomm ,
Remand ,
Reversal ,
Sherman Act ,
Standard Essential Patents